Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Pancreatic ductal adenocarcinoma screening: new perspectives.

Pezzilli R, Fabbri D, Imbrogno A.

World J Gastroenterol. 2012 Sep 28;18(36):4973-7. doi: 10.3748/wjg.v18.i36.4973.

2.

Advances in pancreatic cancer research: moving towards early detection.

He XY, Yuan YZ.

World J Gastroenterol. 2014 Aug 28;20(32):11241-8. doi: 10.3748/wjg.v20.i32.11241. Review.

3.

Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.

Distler M, Pilarsky E, Kersting S, Grützmann R.

Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.

4.

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.

Uno K, Azuma T, Nakajima M, Yasuda K, Hayakumo T, Mukai H, Sakai T, Kawai K.

J Gastroenterol Hepatol. 2000 Nov;15(11):1333-8.

PMID:
11129230
5.

Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.

Akashi T, Oimomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawata H, Watanabe T.

Pancreas. 2003 Jan;26(1):49-55.

PMID:
12499917
6.

Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma.

Mathew BM, Daas AY, Centeno BA, Hoffe S, Valone T, Patel M, Springett GM.

Clin Adv Hematol Oncol. 2012 May;10(5):340-3. No abstract available.

PMID:
22706548
7.

Urine test can detect early stage pancreatic cancer.

Bagcchi S.

Lancet Oncol. 2015 Sep;16(9):e431. doi: 10.1016/S1470-2045(15)00213-2. Epub 2015 Aug 6. No abstract available.

PMID:
26256762
8.

[Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].

Kawaida H, Fujii H.

Nihon Rinsho. 2015 Mar;73 Suppl 3:181-5. Japanese. No abstract available.

PMID:
25857011
9.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.

PMID:
19789838
10.

Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.

Joergensen MT, Brünner N, De Muckadell OB.

Anticancer Res. 2010 Feb;30(2):587-92.

PMID:
20332475
11.

Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.

Fong ZV, Winter JM.

Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea. Review.

PMID:
23187839
12.
13.

Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?

Babic A, Wolpin BM.

Clin Chem. 2016 Feb;62(2):307-9. doi: 10.1373/clinchem.2015.246538. Epub 2015 Dec 31. No abstract available.

14.

Pancreatic cancer and cancer screening programs: from nihilism to hope.

Pezzilli R, Corinaldesi R, Morselli-Labate AM.

JOP. 2010 Nov 9;11(6):654-5. No abstract available.

15.

Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.

Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, Song SY, Kim H, Hancock WS, Paik YK.

J Proteome Res. 2014 Nov 7;13(11):4878-88. doi: 10.1021/pr5002719. Epub 2014 Aug 8.

PMID:
25057901
16.

Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.

Del Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J, Haas SL, Segersvärd R, Andren-Sandberg Å, Löhr JM.

JAMA Surg. 2015 Jun;150(6):512-8. doi: 10.1001/jamasurg.2014.3852.

PMID:
25853369
17.

Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.

Park HD, Kang ES, Kim JW, Lee KT, Lee KH, Park YS, Park JO, Lee J, Heo JS, Choi SH, Choi DW, Kim S, Lee JK, Lee SY.

Proteomics. 2012 Dec;12(23-24):3590-7. doi: 10.1002/pmic.201200101.

PMID:
23065739
18.

Pictorial essay: multimodality imaging of metastases from pancreatic ductal adenocarcinoma.

Ozkan E, Balachandran A, Bhosale PR, Tamm EP, Marcal LP, Szklaruk J.

Clin Imaging. 2010 Jul-Aug;34(4):277-87. doi: 10.1016/j.clinimag.2009.06.026. Review.

PMID:
20630340
19.

Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal papillary mucinous neoplasm: a case report.

Tamura K, Ohtsuka T, Ideno N, Aso T, Kono H, Nagayoshi Y, Shindo K, Ushijima Y, Ueda J, Takahata S, Ito T, Oda Y, Mizumoto K, Tanaka M.

JOP. 2013 Jul 10;14(4):450-3. doi: 10.6092/1590-8577/1494.

20.

Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Laeseke PF, Chen R, Jeffrey RB, Brentnall TA, Willmann JK.

Radiology. 2015 Dec;277(3):644-61. doi: 10.1148/radiol.2015141020.

Supplemental Content

Support Center